Automated ELISA on-chip for the detection of anti-SARS-CoV-2 antibodies

2.1 Sample collection and preparation

Blood samples were collected according to the protocol approved by the Institutional Review Board of the Alfa Medical Center with number AMCCI-TECCOVID-001. All the participants provided written informed consent before sample collection, which took place in a clinical laboratory, that followed the guidelines established by Official Mexican Standards: NOM-007-SSA3-2011, NOM-087-SEMARNAT-SSA1-2002, NOM-010-SSA2-2010, NOM-006-SSA2-2013, and NMX-EC-15189 IMNC-2015. Blood samples were centrifuged at 1,000 g for 10 minutes at 4°C to separate the serum. In this work, a total of 22 serum samples were analyzed, 7 of them belonged to COVID-19 patients (samples from 3- and 7- months post-infection were available for 2 patients, while only samples from 7-months post-infection were available for the other 5 patients), 4 were from vaccinated volunteers (samples from 0- and 60-days post-vaccine were available for 2 patients, while only samples from 60-days post-vaccine were available for the other 2 patients), and 7 corresponded to healthy volunteers (2 samples were taken before the COVID-19 pandemic started). BSA was included as a negative control. All positive and negative samples were confirmed by qRT-PCR. All procedures involving human participants were performed in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

2.2 Traditional ELISA on a microplate

A traditional ELISA was performed using a 96-well microplate (Corning Inc., MA, USA) to compare those results against the ones obtained with our automated ELISA on-chip. Firstly, 100 µL of a PBS suspension containing 1 µg/mL of the complete spike protein (Sino Biological Inc., PA, USA) were deposited in each well, followed by a 1 hour incubation at room temperature. Afterward, three washes were made using a wash buffer (WB = PBS containing 0.05% TweenTM 20 (Thermo Fisher Scientific, MA, USA)). Blocking was made by incubating for 1 hour 200 µL of 5% skim milk (Sigma-Aldrich, MA, USA) at room temperature. Subsequently, another round of three washes were carried out using the WB. Then, the serum samples (1:100 dilution) were added to the microplate and incubated for 1 hour at room temperature, to later be washed three times with WB. Next, a 1 hour incubation of 100 µL of anti-human IgG conjugated with HRP (1:15,000 dilution) (Thermo Fisher Scientific, MA, USA) was performed, at room temperature, to identify the presence of anti-spike antibodies; followed by three washes with WB. Finally, 100 μL of 1-StepTM Ultra TMB-ELISA (Pierce Biotechnology Inc., IL, USA) were used to reveal the reaction, and the reaction was stopped by adding 100 μL of 1M H2SO4.

2.3 Assay’s methodology and experimental setup of the automated ELISA on-chip

The methodology followed in the automated ELISA on-chip assay and a diagram that illustrates the experimental setup implemented are displayed in Figures 1A and 1B, respectively. The reagents used and the conditions at which these were passed through the microfluidic device are specified in Table 1.

• Download figure
• Open in new tab

Figure 1.

Assay’s methodology and experimental setup. A) The methodology followed in our automated ELISA on-chip assay included the steps listed below: 1) Blood collection and serum extraction, 2) On-chip immobilization of viral antigens (SARS-CoV-2 spike protein), 3) Pumping serum samples through the microfluidic device (if present, anti-SARS-CoV-2 antibodies interact with the immobilized SARS-CoV-2 spike proteins), 4) Pumping anti-IgG-HRP through the micro-fluidic device to detect IgG antibodies, and 5) Analysis of the colorimetric reaction, either by re-covering the resulting reaction and performing the analysis with a microplate reader or by car-rying out a color intensity analysis using ImageJ software. B) Diagram of the experimental setup assembled for our automated ELISA on-chip. The components are listed below: 1) Software that controls all the peripheral devices of the setup, 2) Flow control unit, 3) ELISA reagents (wash buffer, blocking buffer, and anti-IgG-HRP conjugate antibody), 4) 12/1 bidirectional microfluidic rotary valve, 5) Serum samples, 6) Microfluidic valve controller, 7) Pinch valves, 8) 3/2-way switching valves, 9) Microfluidic device, and 10) Connections between components and reser-voirs (color code: blue is for pneumatic connections, green is for fluid connections, and black is for electrical connections).

Commercially available microfluidic instrumentation was used to assemble the experimental setup that enabled the automation of our ELISA on-chip assay, from antigen immobilization to the detection of an-ti-SARS-CoV-2 antibodies. A PS microfluidic device with four straight channels (50 µL volume capacity/channel) (microfluidic ChipShop, Jena, Germany), a flow control unit (Zen Fluidics, TX, USA), a 12/1 bidirectional microfluidic rotary valve (Zen Fluidics, TX, USA), a microfluidic valve controller (Zen Fluidics, TX, USA), a set of 4 pinch valves (Zen Fluidics, TX, USA), and a set of 4 3/2-way switching valves (Zen Fluidics, TX, USA) were the main components that constitute this setup. All protocol steps were programmed using the Zen Lab software (Zen Fluidics, TX, USA), which also served to control all the components of the setup. All the pneumatic, fluidic, and electrical connections are also specified in the diagram depicted in Figure 1B. Additionally, a photograph of the experimental setup is shown in Figure 2.

• Download figure
• Open in new tab

Figure 2.

A) Photograph of the experimental setup of our automated ELISA on-chip. B) Picture of the microfluidic device used in our setup.

2.4 Data analysis

The colorimetric reactions obtained when performing the traditional ELISA and our automated ELISA on-chip were analyzed with two different methods. The first one used a microplate reader (BioTek Instruments, VT, USA) and measured the reaction at 450 nm. The second approach was based on taking photos with a commercial smartphone, of the microplate and microfluidic devices, under same lighting conditions, for further color intensity analysis using the color histogram plugin of the ImageJ software (NIH, MD, USA) to assign a value to each reaction.

2.5 Statistical analysis

The Kolmogorov-Smirnov test was used to determine if our data followed a normal distribution. The results showed non-parametric behavior; therefore, the statistical analysis was performed with the Wilcoxon test, using a p-value < 0.01 and the IBM SPSS Statistics 27 software (IBM Corporation, NY, USA). All samples were run in triplicate. DataGraph version 4.7 (Visual Data Tools Inc., NC, USA) and Microsoft Excel (Microsoft Corporation, WA, USA) were employed to graph the results.

3.1. Immunoassays’ comparison

To validate our results, we performed a comparison between the traditional ELISA and our automated ELISA on-chip, in which anti-SARS-CoV-2 antibodies were detected. For both immunoassay formats, the colorimetric reactions derived from the horseradish peroxidase were analyzed with a microplate reader (Figure 3A). The 22 samples used in this work were collected from COVID-19 patients, vaccinated individuals, and healthy volunteers. The results showed a non-parametric distribution; therefore, the Wilcoxon test was employed to make the statistical analysis, indicating that there wasn’t a statistically significant difference between both immunoassays.

• Download figure
• Open in new tab

Figure 3.

Absorbance comparison between the traditional ELISA and our automated ELISA on-chip. The resulting colorimetric reactions from both immunoassay formats were analyzed with a microplate reader. A) Measured absorbance of the 22 serum samples and 1 negative control. The dotted line indicates the average absorbance measured in serum samples from healthy subjects. B) Measured absorbance of the serum samples collected from COVID-19 patients 3 months (circle) and 7 months (cross) after infection. C) Measured absorbance of the serum samples collected from vaccinated individuals prior being vaccinated (triangle) and 60 days after vaccination (square).

3.2. Detection of anti-SARS-CoV-2 antibodies post-infection

We also monitored the presence of anti-SARS-CoV-2 antibodies in 2 patients diagnosed with COVID-19 at 3- and 7-months post-infection. In these patients, a decrease in absorbance was observed in samples collected 7 months after infection compared to the samples collected 3 months post-infection.

Furthermore, for the other 5 patients, only samples from 7 months post-infection were available, which showed comparable, or even higher antibody levels. The data obtained from both immunoassay formats, the traditional ELISA, and the automated ELISA on-chip, are displayed in Figure 3B.

The immune response after COVID-19 infection is heterogeneous among subjects, whereas, for diseases caused by other coronaviruses, such as SARS-CoV and MERS-CoV, antibodies can be detected up to 34 weeks after being infected [27,28]. As an example, Labriola et al. reported a decline in anti-spike and anti-nucleocapsid IgG levels in patients that tested positive for COVID-19, 3 months after infection, while Dan et al. reported stable levels of anti-SARS-CoV-2 antibodies after 8 months from viral infection. Despite this heterogeneity, the immune response seen in patients after infection agrees with what has been described in other reports [29–32].

3.3. Detection of anti-SARS-CoV-2 antibodies post-vaccine

In this study, we also analyzed serum samples from four vaccinated individuals. Blood was collected and processed 60 days after vaccination. To assess the increase of anti-SARS-CoV-2 antibodies after inoculation, we collected two samples from two of those individuals before they were vaccinated. As seen in Figure 3C, using both assay formats, high levels of anti-SARS-CoV-2 antibodies were detected in the four samples extracted 60 days after vaccination. Furthermore, the immune response triggered by the administration of this biologic can be observed on the two patients that had samples available before and after vaccination.

In an effort to control this pandemic, different immunization strategies have been developed. Currently, the FDA has approved three different vaccines based on either adenovirus or lipidic complexes containing mRNA molecules. In a recent work by Jalkanen et al., an increase in the production of anti-SARS-CoV-2 IgG antibodies was observed at six weeks after the administration of the mRNA vaccine (BNT162b2). Additionally, Stephenson et al. reported a detectable increase of anti-SARS-CoV-2 antibodies eight days after the administration of the adenoviral Ad26.COV2.S vaccine, detecting higher concentrations of these antibodies 57 and 71 days after inoculation. The results obtained in this work are in line with the results reported in other studies where these biologics were assessed, which showed an increase of anti-SARS-CoV-2 antibodies after the application of a vaccine [33–35].

3.4 Image analysis of colorimetric reactions

Diagnostic tests usually require expensive equipment and/or specialized technicians, which complicates its implementation in underdeveloped communities. Therefore, we propose to use photographs taken with a commercial smartphone to perform the analysis of the resulting colorimetric reaction as a simple and low-cost alternative to microplate readers. We were able to detect anti-SARS-CoV-2 antibodies in serum samples from COVID-19 patients, and individuals vaccinated using both immunoassay formats and assigning a value to each reaction by analyzing the color intensity of every picture taken. Figure 4A visually describes the analysis process, while pictures of the resulting reactions when performing the traditional ELISA and our automated ELISA on-chip are shown in Figure 4B. Since both results, the ones obtained from the microplate reader and the analysis with ImageJ, showed a non-parametric distribution, the Wilcoxon test was used to make the statistical analysis, revealing that there were no statistically significant differences between these two approaches. These results are displayed in Figure 4C. There is a clear trend towards the development of point of care (POC) diagnostic devices to mitigate healthcare deficiencies and improve the health conditions of people living in underserved communities. Its popularization is largely due to their compatibility to be mass produced, ease of operation, small footprint, lower costs, and the capacity to rapidly generate accurate and reliable results. To date, numerous POC devices have been developed for its use in a broad range of medical and biomedical applications, including the detection of infectious diseases, such as Zika [36], Ebola [37], and now, COVID-19 [38]. Furthermore, various have been cleared by FDA and are commercially available [39]. There are currently many things left to know regarding the immune response to COVID-19 and its vaccines. To facilitate this knowledge, it is extremely necessary a re-liable, high-throughput, and automated method for quantitatively measure an-ti-SARS-CoV-2 antibodies. Therefore, in this manuscript, we propose an automated ELISA on-chip to detect anti-SARS-CoV-2 antibodies in serum samples. This approach can still increase the number of samples to be processed as well as reducing the time needed to do so; it could also be used for other applications.

• Download figure
• Open in new tab

Figure 4.

A) Analysis methodology: First, the immunoassay is performed. Then, a photograph of the substrate, either a microplate or a microfluidic device, is acquired with a smartphone, fol-lowed by a color intensity analysis of the resulting colorimetric reactions using the ImageJ soft-ware or any other similar software. Finally, the results are plotted and compared against the ones obtained from other samples. B) Photographs of the resulting reactions when performing (1) our automated ELISA on-chip and (2) the traditional ELISA, and its corresponding processed images (3, 4). C) Comparison of the results obtained by image analysis of the colorimetric reactions with both immunoassay formats from the 22 serum samples and 1 negative control.